Drug Trial Radar · NCT01499277
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
Last checked: Nov 19, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
802
Actual
Start
May 2012
Primary completion
Jun 2014
Study completion Jan 2015
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Forest Laboratories
- First posted
- Dec 26, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effects of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in treatment of patients with complicated bacterial skin and soft tissue infections.
Conditions
- Complicated Skin and Soft Tissue Infection
Interventions
Ceftaroline fosamilDrug
IV ceftaroline 600mg every 8 hours
VancomycinDrug
IV vancomycin 15mg/kg every 12 hours
AztreonamDrug
IV aztreonam 1 g every 8 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Response at Test of Cure (TOC) in Modified Intent-to-treat (MITT) Analysis SetTime frame: 7 to 20 days after the last dose of study drug
- Clinical Response at TOC in Clinically Evaluable (CE) Analysis SetTime frame: 7 to 20 days after the last dose of study drug
Locations
91 sites in 28 countries. Site status is shown where the registry gives one.
Research Site
Chula Vista, California
Research Site
Orlando, Florida
Research Site
West Palm Beach, Florida
Research Site
Carmel, Indiana
Research Site
Hazard, Kentucky
Research Site
Springfield, Massachusetts
Research Site
Detroit, Michigan
Research Site
Las Vegas, Nevada
Research Site
Garden City, New York
Research Site
Bellaire, Texas
Research Site
Córdoba, Argentina
Research Site
Santa Fe, Argentina
Research Site
Parkville, Australia
Research Site
Brussels, Belgium
Research Site
Belo Horizonte, Brazil
Research Site
Passo Fundo, Brazil
Research Site
Salvador, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
Pleven, Bulgaria
Research Site
Rousse, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Temuco, Chile
Research Site
Viña del Mar, Chile
Research Site
Beijing, China
Research Site
Changchun, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Fuzhou, China
Research Site
Guangzhou, China
Research Site
Haikou, China
Research Site
Nanning, China
Research Site
Qingdao, China
Research Site
Shanghai, China
Research Site
Shenyang, China
Research Site
Shijiazhuang, China
Research Site
Wuhan, China
Research Site
Xi'an, China
Research Site
Slavonski Brod, Croatia
Research Site
Zagreb, Croatia
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.